Across TCGA pan-cancer cohorts, CERKL Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CERKL data layer compared with 22 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CERKL Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CERKL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, LIHC, and LUSC are the cancer types where CERKL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.964	0.622	.010	12	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.521	0.780	.005	10	view →
SKCM	DFS	Median	III,IV	0.165	0.547	.043	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CERKL tumor-vs-normal RNA expression · all CERKL data types